Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial
In brief
Ixekizumab plus tirzepatide: 39% achieved 50% joint improvement and 10% weight loss
At 52 weeks, 39.2% of adults with psoriatic arthritis and overweight or obesity taking both drugs achieved at least 50% improvement in joint symptoms and lost at least 10% of their weight, versus 1.7% taking ixekizumab alone. The randomized trial also found broader disease and metabolic improvements, but week 52 outcomes were exploratory, and longer-term benefits remain unknown.
- Journal
- Arthritis & rheumatology (Hoboken, N.J.) (Q1)
- Published
- 11 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Joseph F Merola, Cynthia E Kartman, Peter Fischer, Philip Mease, Alan Kivitz, Naveed Sattar, et al.
- PMID
- 43012507
- DOI
- 10.1002/art.70375
Why clinicians should know about it
- Picked for Dermatology (top studies of the week, 15 November 2026): Randomized trial reports dermatologic outcomes with psoriasis therapy
Abstract
OBJECTIVE: Obesity or overweight occurs in 72% to 82% of individuals with psoriatic arthritis (PsA). Previous data revealed greater disease control with concomitant ixekizumab (IXE) and tirzepatide (TZP) versus IXE alone in adults with active PsA and obesity or overweight with at least one weight-related comorbidity at the week 36 primary end point. The objective of this report is to evaluate the effect of IXE+TZP versus IXE on psoriatic disease control and safety measures up to week 52. METHODS: TOGETHER-PsA (ClinicalTrials.gov ID NCT06588296) is a phase 3b, randomized, open-label, assessor-blinded 52-week trial. Participants were randomized 1:1 to IXE+TZP or IXE using US-approved doses. Week 52 outcomes were prespecified, non-multiplicity-controlled, and exploratory. Outcomes included 50% improvement in American College of Rheumatology response criteria (ACR50) and rheumatologic, dermatologic, patient-reported, metabolic, and safety outcomes. RESULTS: A total of 271 participants were randomized (IXE+TZP, n = 138; IXE, n = 133). The proportion achieving the primary outcome of simultaneous ACR50 and ≥10% weight reduction continued to increase from week 36 through week 52 for IXE+TZP (39.2%) versus IXE (1.7%) (Δ37.5%; P < 0.001). ACR50 continued to diverge after week 36, with a clinically meaningful difference at week 52 for IXE+TZP (43.7%) versus IXE (15.7%) (Δ 28.0%; P < 0.001). IXE+TZP demonstrated significant improvements in ACR20, minimal disease activity, Disease Activity Index for Psoriatic Arthritis, patient-reported outcomes, and metabolic outcomes versus IXE alone. Safety profiles were consistent with previous studies for each drug. CONCLUSION: Comprehensive improvements in disease activity, including ACR50, quality of life, weight, and metabolic outcomes, continued through week 52 and were greater with IXE+TZP than IXE alone, with no new safety concerns. These findings support concomitant IXE+TZP in patients with active PsA and immunometabolic disease.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.